Open AccessA new statin: A new standard
Author(s) -
Olsson Anders G.
Publication year - 2001
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960241505
Subject(s) - rosuvastatin , medicine , pravastatin , simvastatin , atorvastatin , statin , rosuvastatin calcium , placebo , ldl cholesterol , hmg coa reductase , observational study , secondary prevention , pharmacology , cholesterol , cardiology , reductase , biochemistry , chemistry , alternative medicine , pathology , enzyme
Summary : Numerous studies have demonstrated that treatments designed to reduce low‐density lipoprotein cholesterol (LDL‐C) can reduce the risk of coronary heart disease (CHD) events in the setting of either primary or secondary prevention. The rationale for aggressive lowering of LDL‐C, supported by large observational studies, is the concept that no threshold exists below which reductions fail to provide additional benefit. The statins are widely considered first‐line therapy for preventing CHD events because these agents yield the greatest reductions in LDL‐C. However, many patients do not achieve target LDL‐C levels with the currently available statins. Newer, more effective statins may permit the benefits of aggressive LDL‐C reduction to be extended to larger numbers of patients. A novel, highly efficacious statin, rosuvastatin (Crestor TM , AstraZeneca group of companies), is currently undergoing clinical investigation. Dose‐ranging studies in hypercholesterolemic patients have shown that rosuvastatin produces significant, dose‐dependent decreases in LDL‐C when compared with placebo. Reductions have ranged from 34% at a dose of 1 mg/day to 65% at 80 mg/day. This agent has been found to be well tolerated across the range of doses studied. Phase III studies indicate that rosuvastatin is more effective than atorvastatin, pravastatin, and simvastatin in improving the atherogenic lipid profiles of hypercholesterolemic patients, and more effective than atorvastatin in improving the atherogenic lipid profiles of patients with heterozygous familial hypercholesterolemia. Overall, these findings suggest that rosuvastatin is a promising new medication for the treatment of dyslipidemias.